{"title":"扩大基于 GLP1 的疗法的应用范围","authors":"Daniel J. Drucker","doi":"10.1038/s41574-024-01066-9","DOIUrl":null,"url":null,"abstract":"The evidence base in support of the use of medicines based on glucagon-like peptide 1 beyond glucose control and weight loss was substantially bolstered in 2024, as clinical trial data report benefits of these medicines in people with a range of disorders.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 2","pages":"65-66"},"PeriodicalIF":31.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expanding applications of therapies based on GLP1\",\"authors\":\"Daniel J. Drucker\",\"doi\":\"10.1038/s41574-024-01066-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The evidence base in support of the use of medicines based on glucagon-like peptide 1 beyond glucose control and weight loss was substantially bolstered in 2024, as clinical trial data report benefits of these medicines in people with a range of disorders.\",\"PeriodicalId\":18916,\"journal\":{\"name\":\"Nature Reviews Endocrinology\",\"volume\":\"21 2\",\"pages\":\"65-66\"},\"PeriodicalIF\":31.0000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Endocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41574-024-01066-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41574-024-01066-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
The evidence base in support of the use of medicines based on glucagon-like peptide 1 beyond glucose control and weight loss was substantially bolstered in 2024, as clinical trial data report benefits of these medicines in people with a range of disorders.
期刊介绍:
Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.